Selection of an early biomarker for vascular normalization using dynamic contrast-enhanced ultrasonography to predict outcomes of metastatic patients treated with bevacizumab.
about
Liposomal 64Cu-PET Imaging of Anti-VEGF Drug Effects on Liposomal Delivery to Colon Cancer Xenografts.Revisiting Bevacizumab + Cytotoxics Scheduling Using Mathematical Modeling: Proof of Concept Study in Experimental Non-Small Cell Lung Carcinoma.Monitoring of tumor vascular normalization: the key points from basic research to clinical application
P2860
Selection of an early biomarker for vascular normalization using dynamic contrast-enhanced ultrasonography to predict outcomes of metastatic patients treated with bevacizumab.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Selection of an early biomarke ...... ents treated with bevacizumab.
@en
Selection of an early biomarke ...... ents treated with bevacizumab.
@nl
type
label
Selection of an early biomarke ...... ents treated with bevacizumab.
@en
Selection of an early biomarke ...... ents treated with bevacizumab.
@nl
prefLabel
Selection of an early biomarke ...... ents treated with bevacizumab.
@en
Selection of an early biomarke ...... ents treated with bevacizumab.
@nl
P2093
P2860
P50
P356
P1433
P1476
Selection of an early biomarke ...... ents treated with bevacizumab.
@en
P2093
B Benatsou
C Labbe-Devilliers
J Uzan-Augui
L M Caquot
P2860
P304
P356
10.1093/ANNONC/MDW280
P577
2016-08-08T00:00:00Z